Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.

"Declaration of Competing Interest Since the Editor-in-Chief of Immunobiology, Hans-Wilhelm Schwaeble, has been collaborating with and consulting for Omeros Corporation, this manuscript was edited by Associate Editor Teizo Fujita, who has no conflict of interest to declare. AR: consulting/advisory fees and travel expenses from Omeros, Amgen, Novartis, Roche/Genentech, Astellas, and Italfarmaco; Celgene and Sanofi, outside the submitted work. FDM: grants and personal fees from Boehringer Ingelheim, GSK, Chiesi, Zambon, Novartis, Guidotti/Malesci, AstraZeneca, Menarini, Mundipharma, TEVA, Almiral, outside the submitted work. GR: personal fees and non-financial support from Alexion Pharmaceuticals Inc, Janssen Pharmaceutical, Akebia Therapeutics, Alnylam, Boehringer Ingelheim, Inception Sciences Canada, outside the submitted work. SW, GD: employed by and holds stock in Omeros Corporation. GG, MCM, MF, GB, ASa, FL, CP, ASo, AG, FB, SF, LL: No relationships to disclose."

"This study was funded by AIL - Associazione italiana contro le leucemie-linfomi e mieloma (AIL) and by the Italian Association for Cancer research (AIRC, project 5x1000, ID 21147 to AR)."